ObesityMIPSNCT02269410
Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss
A study testing GBP-SPS, GBP-HPS and VSG-SPS in people with Obesity, run by Columbia University.
Trial summary
The obesity epidemic has grown rapidly in the United States, and is associated with increased morbidity and mortality rates. Bariatric surgery (BS) has emerged as the most effective treatment for severe obesity. Surgical weight loss (WL) is very significant (~40-50kg) during the first 6-12 months after surgery. Read more about this study
- Who is it for?
- Ages 18 to 65 years, women only
- Conditions the study is for
- Obesity
- What is being tested?
- GBP-SPS, GBP-HPS and VSG-SPS
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- No sites listed yet
- Study dates
- Nov 2014to Feb 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Women scheduled to undergo either GBP or VSG.
- Ethnicity/gender: People of all race/ethnicity are eligible to participate, so that the study will reflect a diverse population.
- Non diabetic or diet controlled diabetic with no medication
Who cannot join
- Individuals who have a clinical history strongly suggestive of type 1 diabetes mellitus or T2DM will be excluded.
- Nitrogen retention disease such as renal or hepatic disease.
- Known malabsorption syndrome.
- Any other condition which, in the opinion of the investigators, may make the candidate unsuitable for participation in this study.
About this study
Official title: Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss II (MIPS II)
The obesity epidemic has grown rapidly in the United States, and is associated with increased morbidity and mortality rates. Bariatric surgery (BS) has emerged as the most effective treatment for severe obesity. Surgical weight loss (WL) is very significant (~40-50kg) during the first 6-12 months after surgery. The adequate amount of dietary protein during the active period of surgical weight loss is not known. Dietary protein affects body weight regulation: satiety, thermogenesis, energy efficiency and body composition. During diet-induced energy-restriction, sustaining protein intake (PI) at the level of requirement (0.8g /kg ideal body weight (IBW)/ day) appears to preserve fat free mass (FFM) during active WL. PI above requirements (1.2g protein/Kg IBW/ day) results in favorable body composition changes, with greater decrease in fat mass and preservation of FFM, but without effecting WL. Dietary PI 0.8g/day has been associated with greater satiety and increased energy expenditure (EE) during calorie restriction. In this randomized prospective study, the investigators will evaluate the effect of PI on nitrogen balance, body composition, EE and satiety in 40 women undergoing either Gastric Bypass or Vertical Sleeve Gastrectomy, assigned to high protein supplementation (PRO-S), high PRO-S (1.2g /kg IBW/day) or standard- based current guidelines -PRO-S (0.8g /kg IBW/day). PRO-S will be supplied for 3 months after surgery. Outcome measures including nitrogen balance, body composition changes and satiety will be assessed at pre-surgery, and at 3, 6 and 12 months post-surgery. These results will help provide evidence-based data on safe and optimal levels of protein supplementation after BS
Read the detailed description
The goal of this proposal is to study the effect of dietary protein supplementation (PRO-S) during surgical weight loss, on nitrogen balance, energy expenditure, body composition of weight loss, and satiety. The overall goal is to provide evidence-based data on optimal levels of protein supplementation after surgical weight loss by gastric bypass (GBP), a restrictive and malabsorptive procedure, or by vertical sleeve gastrectomy (VSG), a purely restrictive procedure.
We propose a prospective randomized controlled trial (RCT), in which, patients undergoing either GBP or VSG will be allocated to standard PRO-S recommendation ("standard care" according to the American Society for Metabolic and Bariatric Surgery Guidelines) or high supplementation. We will compare 4 groups of subjects:
- Group 1: GBP Standard PRO-S (0.8g protein/kg ideal body weight (IBW)/day
- Group 2: GBP High PRO-S (1.2g protein/ kg ideal body weight (IBW)/ day)
- Group 3: VSG Standard PRO-S (0.8g protein/kg ideal body weight (IBW)/day
- Group 4: VSG High PRO-S (1.2g protein/ kg ideal body weight (IBW)/ day)
AIM#1: Measure total body nitrogen balance (NB) to assess adequacy of levels of protein intake and protein absorption.
AIM#2: Measure the effect PRO-S on lean body mass (LBM), and resting energy expenditure (REE).
AIM#3: Measure the effect of PRO-S on satiety. Hypothesis 3.1: Patients in the High PRO-S group will experience higher levels of perceived satiety compared with patients in the standard PRO-S group.
AIM #4: Study adherence to protein supplementation. Hypothesis : Adherence will be greater in the Standard PRO-S group.
Background and Significance The obesity epidemic has grown rapidly in the United States, and is associated with increased morbidity and mortality rates. Although preventive measures are needed to solve the obesity epidemic in the long-term, bariatric surgery has become a popular and effective treatment of severe obesity. Obesity and its co-morbidities, including type 2 diabetes (T2DM), have a high health care cost2. The cost is even greater for severe obesity (BMI≥40 kg/m2).
Protein (PRO) malnutrition after bariatric surgery (BS) Bariatric surgery (BS) has emerged as the most effective treatment for severe obesity. Gastric bypass surgery (GBP) results in large weight loss with normalization of metabolic functions, including T2DM remission in ~60-80% of cases. Weight loss is very significant (~40-50kg). The rate of weight loss is rapid during the first year after surgery. Surgical weight loss can be associated with vitamin, mineral, and protein deficiencies. PRO malnutrition, remains the most severe nutritional complication associated with malabsorptive surgical procedures. The prevalence of protein malnutrition after malabsorptive BS procedures varies between 3 to 18% and is associated with the length of the bypassed segment. The US recommended dietary allowance (RDA) for protein is ~50 g/d for healthy normal weight adults. Experts and clinicians recommend ~70 g/d of protein during low-calorie diets or 60 g/day (standard) and 120 g/day (high) in the earlier months after BS. However, there is little evidence-based data to support these recommendations. In spite of the absence of level 1 data on types and amount of protein recommendations, the American Society for Metabolic Surgery and BS's website has 14 links for commercial nutrition supplements14. In this study, we aim to study protein absorption and adequacy of protein intake by nitrogen balance in patients following standard and high PRO-S following BS.
Effects of dietary proteins Dietary PRO-S and amino acids (AA) are important modulators of body weight by affecting various determinants of body weight regulation: satiety, thermogenesis, energy efficiency and body composition. During energy restriction, sustaining protein intake at the level of requirement (0.8g protein/kg ideal body weight (IBW)/ day) appears to be sufficient to induce body weight loss while preserving fat free mass (FFM). Protein intake above requirements (1.2g protein/Kg IBW/ day) results in a greater decrease in fat mass and preservation of FFM, but has no effect on body weight loss.
Nitrogen balance (NB) study The NB method is classically used to determine adequate protein intakes and to measure whole body protein balance in response to nutritional interventions. Prolonged negative nitrogen balance should not be sustained for long periods due its negative impact on overall health.
Risk of decreased lean body mass (LBM) and resting energy expenditure (REE) with surgical weight loss BS results in large weight losses (30-50kg), with both fat mass (FML) and LBM losses. Our previous observational studies aiming to evaluate the relationship between protein intake and loss of LBM following BS have shown that protein intake > 60g/ day is associated with better maintenance of LBM after BS. LBM is the main determinant of REE, explaining 75% of the REE variance with REE being the largest component of 24-h energy expenditure (EE). Reduced EE may trigger weight regain in this population. High PRO-S diets may also benefit this population by increasing EE while preventing LBM loss. Increased EE from dietary protein is attributed to an enhanced thermic effect (23-30%) compared to carbohydrates (5-10%) or lipids (2-3%).
Dietary protein intake and satiety High-protein intake increases satiety despite energy restriction. Proposed mechanisms are as follows: a ketogenic state, relatively elevated plasma amino acid (AA) levels, and anorexigenic hormone concentrations feedback on the central nervous system to prolong the duration before one feels hunger for the next meal (satiety) such as, Peptide YY, Glucagon-Like Peptide -1 and cholecystokinin produced in response to peripheral and central detection of amino acid, and decreased levels of the orexigenic hormone ghrelin.
Protein supplementation and adherence Low protein intake after BS has been reported. PRO-S has always been recommended after BS but its feasibility has not been well addressed in any RCT. We will study adherence to PRO-S. Increasing adherence with dietary recommendation is challenging, but may represent a key strategy to improve the clinical nutritional treatment and outcomes after BS.
- Conditions
- Obesity
- Being tested
- GBP-SPS, GBP-HPS, VSG-SPS, VSG-HPS
- Keywords
- Bariatric Surgery, Nitrogen Balance, Body composition, Protein supplementation, Satiety, Adherence
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GBP-SPSDietary supplement
Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
GBP-HPSDietary supplement
Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
VSG-SPSDietary supplement
Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
VSG-HPSDietary supplement
Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
| Study group | Role | What they receive |
|---|---|---|
| GBP-SPS | Active comparator | GBP Standard PRO-S (0.8g protein/kg ideal body weigh/day) Receives: Dietary Supplement: GBP-SPS |
| GBP-HPS | Experimental | GBP High PRO-S (1.2g protein/ kg ideal body weight/ day) Receives: Dietary Supplement: GBP-HPS |
| VSG-SPS | Active comparator | VSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day) Receives: Dietary Supplement: VSG-SPS |
| VSG-HPS | Experimental | VSG High PRO-S (1.2g protein/ kg ideal body weight/ day) Receives: Dietary Supplement: VSG-HPS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Nitrogen balance (NB)
During inpatient stay. Nitrogen intake and output will be accurately monitored
Measured: Change from baseline of NB at 3 months after surgery
Change in Nitrogen balance (NB)
During inpatient stay. Nitrogen intake and output will be accurately monitored
Measured: Change form 3 month to 12 months
Change in Nitrogen Balance
During inpatient stay. Nitrogen intake and output will be accurately monitored
Measured: Change from baselina to 12 months
Secondary outcomes (3)
Composite outcome measure consisting of Lean body mass (LBM), and resting energy expenditure (REE).
LBM (Kg) will be analyzed by Bod Pod and Total Body Water technique REE will be determined by indirect calorimetry
Measured: 0, 3 and 12 months after surgery
Satiety scores
Hormonals levels and perceived satiety scores will be evaluated
Measured: 0, 3 and 12 months
Adherence score to protein supplementation.
Score of Adherence will be obtained
Measured: 0, 3 and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2014 (estimated)
- Study startNov 2014
- Primary completionFeb 2016
- Study completionFeb 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (30)Papers the sponsor has linked to this study.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Columbia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Columbia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Blandine Laferrere, Columbia University
- Investigators
- Blandine Laferrere, MD, Principal investigator, Columbia UniversityXavier Pi-Sunyer, MD, Principal investigator, Columbia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02269410
- Sponsor's protocol ID
- AAAN6105
- Acronym
- MIPS
- Status last verified
- Jul 2017
- First submitted
- 10 Oct 2014
- Last updated
- 19 Jul 2017
- Results posted
- No
- Data monitoring committee
- No
Publications
Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009 Mar;122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041.
PubMed 19272486Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52. doi: 10.1056/NEJMoa066254.
PubMed 17715408Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab. 2006 Nov;91(11):4223-31. doi: 10.1210/jc.2006-0557. Epub 2006 Sep 5.
PubMed 16954156Byrne TK. Complications of surgery for obesity. Surg Clin North Am. 2001 Oct;81(5):1181-93, vii-viii. doi: 10.1016/s0039-6109(05)70190-0.
PubMed 11589251Stocker DJ. Management of the bariatric surgery patient. Endocrinol Metab Clin North Am. 2003 Jun;32(2):437-57. doi: 10.1016/s0889-8529(03)00002-1.
PubMed 12800540Skroubis G, Sakellaropoulos G, Pouggouras K, Mead N, Nikiforidis G, Kalfarentzos F. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg. 2002 Aug;12(4):551-8. doi: 10.1381/096089202762252334.
PubMed 12194550Brolin RE, Kenler HA, Gorman JH, Cody RP. Long-limb gastric bypass in the superobese. A prospective randomized study. Ann Surg. 1992 Apr;215(4):387-95. doi: 10.1097/00000658-199204000-00014.
PubMed 1558421Dodell GB, Albu JB, Attia L, McGinty J, Pi-Sunyer FX, Laferrere B. The bariatric surgery patient: lost to follow-up; from morbid obesity to severe malnutrition. Endocr Pract. 2012 Mar-Apr;18(2):e21-5. doi: 10.4158/EP11200.CR.
PubMed 22138075Kushner R. Managing the obese patient after bariatric surgery: a case report of severe malnutrition and review of the literature. JPEN J Parenter Enteral Nutr. 2000 Mar-Apr;24(2):126-32. doi: 10.1177/0148607100024002126.
PubMed 10772194Mechanick JI, Youdim A, Jones DB, Timothy Garvey W, Hurley DL, Molly McMahon M, Heinberg LJ, Kushner R, Adams TD, Shikora S, Dixon JB, Brethauer S. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Surg Obes Relat Dis. 2013 Mar-Apr;9(2):159-91. doi: 10.1016/j.soard.2012.12.010. Epub 2013 Jan 19.
PubMed 23537696Keller U. Dietary proteins in obesity and in diabetes. Int J Vitam Nutr Res. 2011 Mar;81(2-3):125-33. doi: 10.1024/0300-9831/a000059.
PubMed 22139563Soenen S, Martens EA, Hochstenbach-Waelen A, Lemmens SG, Westerterp-Plantenga MS. Normal protein intake is required for body weight loss and weight maintenance, and elevated protein intake for additional preservation of resting energy expenditure and fat free mass. J Nutr. 2013 May;143(5):591-6. doi: 10.3945/jn.112.167593. Epub 2013 Feb 27.
PubMed 23446962Laferrere B, Reilly D, Arias S, Swerdlow N, Gorroochurn P, Bawa B, Bose M, Teixeira J, Stevens RD, Wenner BR, Bain JR, Muehlbauer MJ, Haqq A, Lien L, Shah SH, Svetkey LP, Newgard CB. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med. 2011 Apr 27;3(80):80re2. doi: 10.1126/scitranslmed.3002043.
PubMed 21525399Energy and protein requirements: report of a joint FAO-WHO ad hoc expert committee. Rome, 22 March - 2 April 1971. World Health Organ Tech Rep Ser. 1973;522:1-118. No abstract available.
PubMed 4634202Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser. 1985;724:1-206. No abstract available.
PubMed 3937340
Study at a glance
From the registry record, last updated by the sponsor on 19 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss II (MIPS II)
- ClinicalTrials.gov ID
- NCT02269410
- Acronym / sponsor ID
- MIPS / AAAN6105
- Conditions
- Obesity
- Keywords
- Bariatric Surgery, Nitrogen Balance, Body composition, Protein supplementation, Satiety, Adherence
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Columbia UniversityUniversity, hospital or other
- Study start
- Nov 2014 (actual)
- Primary completion
- Feb 2016 (actual)
- Study completion
- Feb 2016 (actual)
- First posted
- 21 Oct 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The obesity epidemic has grown rapidly in the United States, and is associated with increased morbidity and mortality rates. Bariatric surgery (BS) has emerged as the most effective treatment for severe obesity. Surgical weight loss (WL) is very significant (~40-50kg) during the first 6-12 months after surgery. The adequate amount of dietary protein during the active period of surgical weight loss is not known. Dietary protein affects body weight regulation: satiety, thermogenesis, energy efficiency and body composition. During diet-induced energy-restriction, sustaining protein intake (PI) at the level of requirement (0.8g /kg ideal body weight (IBW)/ day) appears to preserve fat free mass (FFM) during active WL. PI above requirements (1.2g protein/Kg IBW/ day) results in favorable body composition changes, with greater decrease in fat mass and preservation of FFM, but without effecting WL. Dietary PI 0.8g/day has been associated with greater satiety and increased energy expenditure (EE) during calorie restriction. In this randomized prospective study, the investigators will evaluate the effect of PI on nitrogen balance, body composition, EE and satiety in 40 women undergoing either Gastric Bypass or Vertical Sleeve Gastrectomy, assigned to high protein supplementation (PRO-S), high PRO-S (1.2g /kg IBW/day) or standard- based current guidelines -PRO-S (0.8g /kg IBW/day). PRO-S will be supplied for 3 months after surgery. Outcome measures including nitrogen balance, body composition changes and satiety will be assessed at pre-surgery, and at 3, 6 and 12 months post-surgery. These results will help provide evidence-based data on safe and optimal levels of protein supplementation after BS
Detailed description
The goal of this proposal is to study the effect of dietary protein supplementation (PRO-S) during surgical weight loss, on nitrogen balance, energy expenditure, body composition of weight loss, and satiety. The overall goal is to provide evidence-based data on optimal levels of protein supplementation after surgical weight loss by gastric bypass (GBP), a restrictive and malabsorptive procedure, or by vertical sleeve gastrectomy (VSG), a purely restrictive procedure.
We propose a prospective randomized controlled trial (RCT), in which, patients undergoing either GBP or VSG will be allocated to standard PRO-S recommendation ("standard care" according to the American Society for Metabolic and Bariatric Surgery Guidelines) or high supplementation. We will compare 4 groups of subjects:
- Group 1: GBP Standard PRO-S (0.8g protein/kg ideal body weight (IBW)/day
- Group 2: GBP High PRO-S (1.2g protein/ kg ideal body weight (IBW)/ day)
- Group 3: VSG Standard PRO-S (0.8g protein/kg ideal body weight (IBW)/day
- Group 4: VSG High PRO-S (1.2g protein/ kg ideal body weight (IBW)/ day)
AIM#1: Measure total body nitrogen balance (NB) to assess adequacy of levels of protein intake and protein absorption.
AIM#2: Measure the effect PRO-S on lean body mass (LBM), and resting energy expenditure (REE).
AIM#3: Measure the effect of PRO-S on satiety. Hypothesis 3.1: Patients in the High PRO-S group will experience higher levels of perceived satiety compared with patients in the standard PRO-S group.
AIM #4: Study adherence to protein supplementation. Hypothesis : Adherence will be greater in the Standard PRO-S group.
Background and Significance The obesity epidemic has grown rapidly in the United States, and is associated with increased morbidity and mortality rates. Although preventive measures are needed to solve the obesity epidemic in the long-term, bariatric surgery has become a popular and effective treatment of severe obesity. Obesity and its co-morbidities, including type 2 diabetes (T2DM), have a high health care cost2. The cost is even greater for severe obesity (BMI≥40 kg/m2).
Protein (PRO) malnutrition after bariatric surgery (BS) Bariatric surgery (BS) has emerged as the most effective treatment for severe obesity. Gastric bypass surgery (GBP) results in large weight loss with normalization of metabolic functions, including T2DM remission in ~60-80% of cases. Weight loss is very significant (~40-50kg). The rate of weight loss is rapid during the first year after surgery. Surgical weight loss can be associated with vitamin, mineral, and protein deficiencies. PRO malnutrition, remains the most severe nutritional complication associated with malabsorptive surgical procedures. The prevalence of protein malnutrition after malabsorptive BS procedures varies between 3 to 18% and is associated with the length of the bypassed segment. The US recommended dietary allowance (RDA) for protein is ~50 g/d for healthy normal weight adults. Experts and clinicians recommend ~70 g/d of protein during low-calorie diets or 60 g/day (standard) and 120 g/day (high) in the earlier months after BS. However, there is little evidence-based data to support these recommendations. In spite of the absence of level 1 data on types and amount of protein recommendations, the American Society for Metabolic Surgery and BS's website has 14 links for commercial nutrition supplements14. In this study, we aim to study protein absorption and adequacy of protein intake by nitrogen balance in patients following standard and high PRO-S following BS.
Effects of dietary proteins Dietary PRO-S and amino acids (AA) are important modulators of body weight by affecting various determinants of body weight regulation: satiety, thermogenesis, energy efficiency and body composition. During energy restriction, sustaining protein intake at the level of requirement (0.8g protein/kg ideal body weight (IBW)/ day) appears to be sufficient to induce body weight loss while preserving fat free mass (FFM). Protein intake above requirements (1.2g protein/Kg IBW/ day) results in a greater decrease in fat mass and preservation of FFM, but has no effect on body weight loss.
Nitrogen balance (NB) study The NB method is classically used to determine adequate protein intakes and to measure whole body protein balance in response to nutritional interventions. Prolonged negative nitrogen balance should not be sustained for long periods due its negative impact on overall health.
Risk of decreased lean body mass (LBM) and resting energy expenditure (REE) with surgical weight loss BS results in large weight losses (30-50kg), with both fat mass (FML) and LBM losses. Our previous observational studies aiming to evaluate the relationship between protein intake and loss of LBM following BS have shown that protein intake > 60g/ day is associated with better maintenance of LBM after BS. LBM is the main determinant of REE, explaining 75% of the REE variance with REE being the largest component of 24-h energy expenditure (EE). Reduced EE may trigger weight regain in this population. High PRO-S diets may also benefit this population by increasing EE while preventing LBM loss. Increased EE from dietary protein is attributed to an enhanced thermic effect (23-30%) compared to carbohydrates (5-10%) or lipids (2-3%).
Dietary protein intake and satiety High-protein intake increases satiety despite energy restriction. Proposed mechanisms are as follows: a ketogenic state, relatively elevated plasma amino acid (AA) levels, and anorexigenic hormone concentrations feedback on the central nervous system to prolong the duration before one feels hunger for the next meal (satiety) such as, Peptide YY, Glucagon-Like Peptide -1 and cholecystokinin produced in response to peripheral and central detection of amino acid, and decreased levels of the orexigenic hormone ghrelin.
Protein supplementation and adherence Low protein intake after BS has been reported. PRO-S has always been recommended after BS but its feasibility has not been well addressed in any RCT. We will study adherence to PRO-S. Increasing adherence with dietary recommendation is challenging, but may represent a key strategy to improve the clinical nutritional treatment and outcomes after BS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| GBP-SPS | Active comparator | Dietary Supplement: GBP-SPSGBP Standard PRO-S (0.8g protein/kg ideal body weigh/day) |
| GBP-HPS | Experimental | Dietary Supplement: GBP-HPSGBP High PRO-S (1.2g protein/ kg ideal body weight/ day) |
| VSG-SPS | Active comparator | Dietary Supplement: VSG-SPSVSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day) |
| VSG-HPS | Experimental | Dietary Supplement: VSG-HPSVSG High PRO-S (1.2g protein/ kg ideal body weight/ day) |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Women scheduled to undergo either GBP or VSG.
- Ethnicity/gender: People of all race/ethnicity are eligible to participate, so that the study will reflect a diverse population.
- Non diabetic or diet controlled diabetic with no medication
Key exclusion criteria (4 listed)
- Individuals who have a clinical history strongly suggestive of type 1 diabetes mellitus or T2DM will be excluded.
- Nitrogen retention disease such as renal or hepatic disease.
- Known malabsorption syndrome.
- Any other condition which, in the opinion of the investigators, may make the candidate unsuitable for participation in this study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GBP-SPSProtein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery. | Dietary supplement | GBP-SPS |
| GBP-HPSProtein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery. | Dietary supplement | GBP-HPS |
| VSG-SPSProtein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery. | Dietary supplement | VSG-SPS |
| VSG-HPSProtein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery. | Dietary supplement | VSG-HPS |
Primary outcome
Change in Nitrogen balance (NB)
Time frame: Change from baseline of NB at 3 months after surgery
During inpatient stay. Nitrogen intake and output will be accurately monitored
Change in Nitrogen balance (NB)
Time frame: Change form 3 month to 12 months
During inpatient stay. Nitrogen intake and output will be accurately monitored
Change in Nitrogen Balance
Time frame: Change from baselina to 12 months
During inpatient stay. Nitrogen intake and output will be accurately monitored
3 secondary outcomes
Composite outcome measure consisting of Lean body mass (LBM), and resting energy expenditure (REE).
Time frame: 0, 3 and 12 months after surgery
Satiety scores
Time frame: 0, 3 and 12 months
Adherence score to protein supplementation.
Time frame: 0, 3 and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Jul 2017.
- Background: PubMed 19272486Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009 Mar;122(3):248-256.e5. doi: 10.1016/j.amjmed.2008.09.041.
- Background: PubMed 17715408Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52. doi: 10.1056/NEJMoa066254.
- Background: PubMed 16954156Shah M, Simha V, Garg A. Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status. J Clin Endocrinol Metab. 2006 Nov;91(11):4223-31. doi: 10.1210/jc.2006-0557. Epub 2006 Sep 5.
- Background: PubMed 11589251Byrne TK. Complications of surgery for obesity. Surg Clin North Am. 2001 Oct;81(5):1181-93, vii-viii. doi: 10.1016/s0039-6109(05)70190-0.
- Background: PubMed 12800540Stocker DJ. Management of the bariatric surgery patient. Endocrinol Metab Clin North Am. 2003 Jun;32(2):437-57. doi: 10.1016/s0889-8529(03)00002-1.
- Background: PubMed 12194550Skroubis G, Sakellaropoulos G, Pouggouras K, Mead N, Nikiforidis G, Kalfarentzos F. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg. 2002 Aug;12(4):551-8. doi: 10.1381/096089202762252334.
- Background: PubMed 1558421Brolin RE, Kenler HA, Gorman JH, Cody RP. Long-limb gastric bypass in the superobese. A prospective randomized study. Ann Surg. 1992 Apr;215(4):387-95. doi: 10.1097/00000658-199204000-00014.
- Background: PubMed 22138075Dodell GB, Albu JB, Attia L, McGinty J, Pi-Sunyer FX, Laferrere B. The bariatric surgery patient: lost to follow-up; from morbid obesity to severe malnutrition. Endocr Pract. 2012 Mar-Apr;18(2):e21-5. doi: 10.4158/EP11200.CR.
- Background: PubMed 10772194Kushner R. Managing the obese patient after bariatric surgery: a case report of severe malnutrition and review of the literature. JPEN J Parenter Enteral Nutr. 2000 Mar-Apr;24(2):126-32. doi: 10.1177/0148607100024002126.
- Background: PubMed 23537696Mechanick JI, Youdim A, Jones DB, Timothy Garvey W, Hurley DL, Molly McMahon M, Heinberg LJ, Kushner R, Adams TD, Shikora S, Dixon JB, Brethauer S. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Surg Obes Relat Dis. 2013 Mar-Apr;9(2):159-91. doi: 10.1016/j.soard.2012.12.010. Epub 2013 Jan 19.
- Background: PubMed 22139563Keller U. Dietary proteins in obesity and in diabetes. Int J Vitam Nutr Res. 2011 Mar;81(2-3):125-33. doi: 10.1024/0300-9831/a000059.
- Background: PubMed 23446962Soenen S, Martens EA, Hochstenbach-Waelen A, Lemmens SG, Westerterp-Plantenga MS. Normal protein intake is required for body weight loss and weight maintenance, and elevated protein intake for additional preservation of resting energy expenditure and fat free mass. J Nutr. 2013 May;143(5):591-6. doi: 10.3945/jn.112.167593. Epub 2013 Feb 27.
- Obesity Update 2012Link provided by the sponsor.
- Unit States Department of agricultureLink provided by the sponsor.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Blandine Laferrere, MD principal investigator
Columbia University
Xavier Pi-Sunyer, MD principal investigator
Columbia University
Questions about this trial
What is this clinical trial studying?
A study testing GBP-SPS, GBP-HPS and VSG-SPS in people with Obesity, run by Columbia University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Nitrogen balance (NB) (time frame: Change from baseline of NB at 3 months after surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02269410, which also lists 30 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jul 2017.